Executive Management

Kevin Sayer is the Chairman of the Board of Directors, President and Chief Executive Officer of Dexcom

Kevin assumed the role of CEO in January 2015 and became Chairman of the Board in July 2018. Kevin has also served as our President since 2011. He held the role of Chief Operating Officer from January 2013 until January 2015. Kevin has served as a member of Dexcom’s Board of Directors beginning in November 2007, prior to his role as Chairman and CEO.

Prior to leading Dexcom, Kevin held various management positions in his prior roles. He served as Chief Financial Officer of Biosensors International Group, Ltd., Executive Vice President and Chief Financial Officer of Specialty Laboratories, Inc., Chief Financial Officer of MiniMed, Inc., and Vice President and General Manager of Medtronic MiniMed after the acquisition of MiniMed by Medtronic.

Kevin is a Certified Public Accountant (inactive) and received a Bachelor’s degree and a Master's degree in Accounting and Information Systems from Brigham Young University.

Donald (“Don”) Abbey is Executive Vice President, Global Business Services, IT, Quality and Regulatory Affairs

Don assumed the role of Executive Vice President, Global Business Services, IT, Quality and Regulatory Affairs in January 2017, and previously served as Executive Vice President, Quality from May 2016 to January 2017.

Don has 30+ years of medical device and pharmaceutical industry experience. Prior to Dexcom, Don served in executive roles for Becton Dickinson (the acquirer of CareFusion which itself was spun off from Cardinal Health), including as Senior Vice President, Quality and Regulatory for Becton Dickinson, as Executive Vice President, Quality, Regulatory and Medical Affairs for CareFusion, as Senior Vice President, Quality and Regulatory for CareFusion, and as Senior Vice President, Quality and Regulatory for Cardinal Health. Prior to 2007, Don held senior quality and regulatory affairs and general management positions with Respironics, Welch Allyn, and Philips Healthcare.

Don received a Bachelor of Science degree in Electrical Engineering from Washington State University and a Master of Business Administration from the University of Washington.

Andrew (“Andy”) Balo is Executive Vice President, Regulatory Strategy, Clinical Affairs and Strategic Partnership Development at Dexcom.

Andy assumed the role of Executive Vice President, Regulatory Strategy, Clinical Affairs and Strategic Partnership Development at Dexcom in May 2016. In this role, Andy is responsible for overseeing Dexcom’s clinical trials worldwide and developing global regulatory strategies related to these activities.

Since joining Dexcom in 2002, Mr. Balo has held several executive roles, including Executive Vice President, Clinical, Regulatory and Quality, Senior Vice President of Clinical and Regulatory Affairs and Vice President of Clinical and Regulatory Affairs.

Prior to joining Dexcom, Andy served as Vice President of Regulatory and Clinical Affairs for InnerCool Therapies and Endocardial Solutions. Andy also held several leadership positions at St. Jude Medical including Vice President, Regulatory, Clinical and Technical Services and Corporate Vice President, Quality, Regulatory and Clinical Affairs and was an officer of the company.

Andy received his Bachelor of Science degree in Microbiology and Chemistry from the University of Maryland and completed graduate studies at UCLA and Stanford University.

Michael Brown is Executive Vice President and Chief Legal Officer at Dexcom, where he has worldwide responsibility for all legal and intellectual property matters.

Before joining Dexcom in 2022, Michael was a partner at DLA Piper, where he served as outside general counsel to companies, advised on important business and legal issues, assisted with corporate governance and executed mergers and acquisitions and financings. Prior to that, he was a partner at Stradling Yocca Carlson & Rauth, where he represented emerging and public technology, life science and other growth companies. Before that, Michael served as outside General Counsel for several high-growth companies.

Michael earned his J.D. from the University of Virginia School of Law and his B.A. from the University of Washington. Michael is a board member of Riding on Insulin, a non-profit organization that connects the global diabetes community through action sports.

Matt Dolan has served as Dexcom’s Executive Vice President of Strategy, Corporate Development & Dexcom Labs since September 2022.

Matt joined Dexcom in 2015 and has held various positions of increasing responsibility. In his current role, Matt is responsible for Dexcom’s corporate strategy and development functions, including long-range planning, strategic and competitive intelligence, partnerships, and M&A. Since its inception in 2019, he also oversees Dexcom’s New Markets incubator, which is focused on expanding the company’s value proposition across new areas of growth for both its Continuous Glucose Monitoring and other sensing capabilities. Before that, Matt’s responsibilities included support of Dexcom’s Investor Relations efforts.

With 20 years of experience in the medical technology space, Matt began his career as an equity analyst on Wall Street, a role he held for 10 years. After that, he held a leadership position in strategy and business development at Volcano Corporation through the company’s acquisition by Philips in 2015.

Matt earned a Bachelor’s degree in Economics/Pre-Medicine from Northwestern University.

Paul Flynn is Executive Vice President, Global Revenue at Dexcom.

Paul assumed the role of Executive Vice President, Global Revenue in March 2021. In this role, he is responsible for global sales and commercial operations. Paul previously held various roles of Senior Vice President, General Manager Americas and Asia Pacific and Vice President, General Manager, Americas and Asia Pacific since joining Dexcom in 2015.

Prior to joining Dexcom, Paul served in numerous leadership capacities at Johnson & Johnson over the span of 23 years, including more than a decade in the diabetes space for both Lifescan and Animas Corporation. While at Johnson & Johnson, Paul established the Animas business in Canada and was also the Director, North American Sales for Animas Corporation.

Paul earned a Bachelor of Business Administration from Simon Fraser University and a Master of Business Administration from Wilfrid Laurier University.

Jacob (“Jake”) Leach has served as our Executive Vice President and Chief Operating Officer at Dexcom since August 2022. Prior to becoming Chief Operating Officer, Jake served as Chief Technology Officer, leading Dexcom’s research, product development, project management and engineering departments.

Jake is responsible for all things product, driving day-to-day decision-making and resource allocation across all major product-facing groups, including global operations, research and development, clinical affairs, and quality management and regulatory. He is also responsible for creating an integrated management structure that strengthens the company’s ability to execute on its vision for long-term sustainable growth.

Jake joined Dexcom in 2004, and for almost 20 years has helped lead technology development at Dexcom. During his tenure, Jake, together with his team, has ensured Dexcom delivers innovative continuous glucose monitoring solutions paired with exceptional experiences to patients, caregivers, and physicians all over the world. Jake and his team are also responsible for the development of the first commercial Dexcom CGM system, and all future generations, including Dexcom G6, the best-selling real-time CGM in the world.

Jake holds a Bachelor of Science degree in Electrical Engineering with a minor in Biomedical Engineering from the University of California, Los Angeles.

Steve Pacelli is Executive Vice President and Managing Director, Dexcom Ventures.

In this role, Steve is focused on investment opportunities in sensing technology, data analytics, remote patient monitoring and population health, broadening Dexcom’s commitment to advancing better outcomes in healthcare.

Prior to this role, Steve was Executive Vice President of Strategy and Corporate Development from 2012 to 2021. Since joining Dexcom in April 2006, Steve has served in roles of increasing responsibility, including Chief Operating Officer, Chief Administrative Officer, Senior Vice President of Corporate Affairs and Vice President of Legal Affairs.

Prior to Dexcom, Steve served as a corporate attorney specializing in finance, mergers and acquisitions, and general corporate matters, and in an executive role as general counsel of several privately held companies.

Steve currently serves as a member of the Board of Directors of Biocom California, the largest and most experienced leader and advocate for California’s life science sector. He also serves as a member of the Board of Directors of Connect, a community nonprofit supporting innovators and entrepreneurs in Southern California by providing access to investors, mentors, and education, and as a member of the Board of Directors of EvoNexus, California’s leading non-profit startup technology incubator.

Steve is also a dedicated philanthropist, choosing to focus his efforts as a member of the Board of Directors of Big Brothers Big Sisters of San Diego, an organization dedicated to creating and supporting one-to-one mentoring relationships that ignite the power and promise of youth. He also serves as a member of the Board of Trustees of Pacific Ridge School, a group of dedicated and informed community leaders who are passionate about the value of education and are committed to building and strengthening the school.

Steve earned a Bachelor of Arts from the University of California, Los Angeles, and a JD from the University of Virginia. He is a member of the State Bar of California.

Barry Regan is Executive Vice President of Global Operations at Dexcom.

Barry joined Dexcom in 2020, and he is responsible for Dexcom’s global Operations teams including Corporate Operations Engineering, Manufacturing, Supply Chain, Procurement, Facilities, Environmental Health Safety and Sustainability, and Operations Program Management. Barry also oversees manufacturing process development and automation and supply chain scale-up of Dexcom’s innovative Continuous Glucose Monitoring products.

With close to 30 years of experience in Operations, Barry has led organizations in the global medical device and pharmaceutical industries through scaling and transformational change efforts to support growth and drive strategy.

Prior to Dexcom, Barry served as Senior Vice President of Global Operations at Wright Medical, leading global Manufacturing, Supply Chain, Engineering, Procurement, Facilities, EHS, and Distribution and Logistics. Before that, Barry was the Senior Vice President Global Supply Chain at Smith & Nephew. He has also served at AbbVie, as Vice President & General Manager, Americas Manufacturing, and has held various positions at Abbott Laboratories, a health care product company, with increasing responsibilities over a 17 year period. Barry also served on the board of directors of the Pharmaceutical Industry Association of Puerto Rico for four years.

He holds a Bachelor of Technology degree from the University of Limerick, Ireland, and a MBA from Lake Forest Graduate School of Management.

Shelly Selvaraj is Senior Vice President and Chief Information Officer at Dexcom.

In this role, Shelly is responsible for the global information technology department at Dexcom. Prior to this role, Shelly served as Vice President, Information Technology since joining Dexcom in 2016.

Shelly has a wide range of experience within global organizations in the fields of supply chain management, healthcare informatics and information technology.

Prior to Dexcom, Shelly held various IT leadership roles at CareFusion, a Becton Dickinson Company, and ResMed in San Diego. Earlier in his career, he worked for Motorola, Inc. and ON Semiconductor Corp. in Phoenix, Arizona.

Shelly received a Bachelor of Engineering in Mechanical Engineering from the University of Madras and a Master of Industrial Engineering from Arizona State University.

Sadie Stern is Executive Vice President and Chief Human Resources Officer at Dexcom.

In this role, Sadie is responsible for Dexcom’s People Strategy. She leads the Global Human Resources function, including Diversity, Equity and Inclusion; Total Rewards; Talent Acquisition; Talent Development; Organization Effectiveness; and HR Operations. She also serves as the strategic business partner to Dexcom’s Executive Committee.

With more than 20 years of experience in Human Resources, she has led global organizations through growth and change. Prior to Dexcom, she served as Executive Vice President, People and Culture at 3D Systems, overseeing all aspects of Human Resources across the company’s operations in 23 countries. Sadie has also worked at Qualcomm, LG Electronics and The Walt Disney Company, leading HR teams and driving organizational transformation.

She holds a Master of Arts in Higher Education from the University of Denver, and a Bachelor of Arts in English from San Diego State University.

Jereme Sylvain is Executive Vice President and Chief Financial Officer at Dexcom.

In this role, Jereme is responsible for Dexcom’s Finance organization and Investor Relations. He previously served as Dexcom’s Senior Vice President of Finance and Chief Accounting Officer and Vice President, Finance and Corporate Controller.

Prior to Dexcom, Jereme held various positions at NuVasive, Inc., including Chief Accounting Officer, Vice President, Finance and Vice President and Corporate Controller. In these roles, he was responsible for NuVasive’s global accounting function, corporate FP&A, treasury, and shared service functions. Jereme has also held leadership roles at Thermo Fisher Scientific and was part of the public accounting firm Ernst & Young LLP.

Jereme received his Certified Public Accounting license after receiving a Bachelor of Science degree in Finance from Arizona State University and a Master of Science in Accountancy from the University of Notre Dame.